Document Classification

Section Type: METHODS

Text: This 8-week, double-blind, randomized, active-controlled study, after 1-4 weeks single-blind placebo run-in period, randomized 1191 patients to receive once-daily aliskiren/amlodipine 150/5 mg (n = 287), aliskiren/HCT 150/12. 5 mg (n = 298), amlodipine/HCT 5/12. 5 mg (n = 296), or aliskiren/amlodipine/HCT 150/5/12. 5 mg (up-titrated from aliskiren/HCT 150/12. 5 mg after initial 3 days) (n = 310) for 4 weeks, followed by forced titration to double the initial dose for the next 4 weeks.